CN105517559A - 用于预防和治疗与c1酯酶抑制剂缺乏相关的病症的c1-inh组合物和方法 - Google Patents
用于预防和治疗与c1酯酶抑制剂缺乏相关的病症的c1-inh组合物和方法 Download PDFInfo
- Publication number
- CN105517559A CN105517559A CN201480014712.7A CN201480014712A CN105517559A CN 105517559 A CN105517559 A CN 105517559A CN 201480014712 A CN201480014712 A CN 201480014712A CN 105517559 A CN105517559 A CN 105517559A
- Authority
- CN
- China
- Prior art keywords
- compositions
- treatment
- particular embodiment
- viscosity
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/16—Blood plasma; Blood serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
Abstract
Description
PH | [C1 INH] | 缓冲液 | t0 | t1 | t2 |
5.9 | 400 | 磷酸盐 | 82.87±0.75 | 胶凝 | 81.10±2.11 |
500 | 84.74±1.24 | 胶凝 | 83.61±1.02 | ||
400 | 组氨酸 | 84.11±1.53 | 胶凝 | 85.34±1.55 | |
500 | 86.36±0.76 | 胶凝 | 82.99±0.64 | ||
6.9 | 400 | 磷酸盐 | 87.14±0.67 | 88.59±0.29 | 85.19±2.00 |
500 | 86.44±1.49 | 85.65±1.32 | 84.07±1.24 | ||
400 | 柠檬酸盐 | 86.67±1.36 | 82.92±1.48 | 86.03±0.87 | |
500 | 86.89±1.24 | 86.74±0.88 | 84.42±1.19 | ||
7.9 | 400 | 磷酸盐 | 86.09±1.14 | 85.29±0.84 | 85.98±0.90 |
500 | 86.47±1.15 | 83.57±1.33 | 84.00±0.97 | ||
400 | tris | 87.14±0.98 | 81.74±7.89 | 86.14±0.81 | |
500 | 88.74±0.82 | 87.24±1.47 | 87.30±0.95 |
pH | [C1 INH] | 缓冲液 | t0 | t1 | t2 |
5.9 | 400 | 磷酸盐 | 68.32±1.04 | 胶凝 | 62.56±0.94 |
500 | 67.19±0.14 | 胶凝 | 61.46±0.14 | ||
400 | 组氨酸 | 64.68±0.42 | 胶凝 | 46.58±1.09 | |
500 | 66.60±0.08 | 胶凝 | 44.48±1.04 | ||
6.9 | 400 | 磷酸盐 | 67.85±0.22 | 55.29±0.36 | |
500 | 67.41±0.36 | 54.79±0.14 | 65.45±0.23 | ||
400 | 柠檬酸盐 | 67.82±0.07 | 56.14±0.41 | 65.49±0.16 | |
500 | 67.43±0.30 | 56.59±0.33 | 65.03±0.36 | ||
7.9 | 400 | 磷酸盐 | 67.85±0.09 | 54.96±0.52 | 61.31±0.25 |
500 | 67.58±0.40 | 55.57±0.56 | 64.98±0.50 | ||
400 | tris | 67.63±0.27 | 55.40±0.30 | 65.70±0.56 | |
500 | 67.67±0.47 | 56.18±0.64 | 66.19±0.84 |
Claims (14)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010362851.6A CN111529708A (zh) | 2013-03-15 | 2014-03-17 | 用于预防和治疗与c1酯酶抑制剂缺乏相关的病症的c1-inh组合物和方法 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361791399P | 2013-03-15 | 2013-03-15 | |
US61/791,399 | 2013-03-15 | ||
PCT/US2014/030309 WO2014145519A2 (en) | 2013-03-15 | 2014-03-17 | C1-inh compositions and methods for the prevention and treatment of disorders associated with c1 esterase inhibitor deficency |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010362851.6A Division CN111529708A (zh) | 2013-03-15 | 2014-03-17 | 用于预防和治疗与c1酯酶抑制剂缺乏相关的病症的c1-inh组合物和方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105517559A true CN105517559A (zh) | 2016-04-20 |
Family
ID=51538486
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010362851.6A Pending CN111529708A (zh) | 2013-03-15 | 2014-03-17 | 用于预防和治疗与c1酯酶抑制剂缺乏相关的病症的c1-inh组合物和方法 |
CN201480014712.7A Pending CN105517559A (zh) | 2013-03-15 | 2014-03-17 | 用于预防和治疗与c1酯酶抑制剂缺乏相关的病症的c1-inh组合物和方法 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010362851.6A Pending CN111529708A (zh) | 2013-03-15 | 2014-03-17 | 用于预防和治疗与c1酯酶抑制剂缺乏相关的病症的c1-inh组合物和方法 |
Country Status (30)
Country | Link |
---|---|
US (9) | US9616111B2 (zh) |
EP (3) | EP3290046B1 (zh) |
JP (9) | JP6184581B2 (zh) |
KR (4) | KR102579789B1 (zh) |
CN (2) | CN111529708A (zh) |
AU (3) | AU2014232912A1 (zh) |
BR (1) | BR112015023207A8 (zh) |
CA (2) | CA3054718A1 (zh) |
CY (2) | CY1119419T1 (zh) |
DE (1) | DE202014011208U1 (zh) |
DK (2) | DK2968434T3 (zh) |
EA (1) | EA201591278A1 (zh) |
ES (2) | ES2639833T3 (zh) |
GB (1) | GB2530921B (zh) |
HK (2) | HK1220403A1 (zh) |
HR (2) | HRP20171269T1 (zh) |
HU (2) | HUE036224T2 (zh) |
IL (2) | IL241549B (zh) |
LT (2) | LT3290046T (zh) |
ME (2) | ME03326B (zh) |
MX (3) | MX2020004724A (zh) |
NZ (2) | NZ710730A (zh) |
PL (2) | PL2968434T3 (zh) |
PT (2) | PT2968434T (zh) |
RS (2) | RS56285B1 (zh) |
SG (2) | SG11201507616VA (zh) |
SI (2) | SI3290046T1 (zh) |
TR (1) | TR201900319T4 (zh) |
WO (1) | WO2014145519A2 (zh) |
ZA (3) | ZA201507604B (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109562149A (zh) * | 2016-08-05 | 2019-04-02 | 德国杰特贝林生物制品有限公司 | C1酯酶抑制剂的药物制剂 |
CN109641031A (zh) * | 2016-08-23 | 2019-04-16 | 德国杰特贝林生物制品有限公司 | 预防与c1酯酶抑制剂缺乏相关的遗传性血管性水肿急性发作的方法 |
CN110769848A (zh) * | 2017-05-16 | 2020-02-07 | 瑞士奥克特珐玛公司 | C1-酯酶抑制剂制剂 |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111529708A (zh) | 2013-03-15 | 2020-08-14 | 夏尔维洛药品公司 | 用于预防和治疗与c1酯酶抑制剂缺乏相关的病症的c1-inh组合物和方法 |
LT3071219T (lt) * | 2013-11-22 | 2019-01-10 | Shire Viropharma Incorporated | Antikūnų sukelto atmetimo gydymo būdai organų transplantacijos pacientuose su c1 esterazės inhibitoriumi |
EP3258911A1 (en) * | 2015-02-20 | 2017-12-27 | CSL Behring GmbH | Pharmaceutical formulations of c1 esterase inhibitor |
EP3302540A4 (en) * | 2015-05-28 | 2018-08-22 | Cornell University | Adeno-associated virus mediated delivery of c1ei as a therapy for angioedema |
BR112018010160A8 (pt) * | 2015-11-19 | 2019-02-26 | Shire Human Genetic Therapies | inibidor da c1 esterase humana recombinante e usos do mesmo |
CN111818938A (zh) | 2018-02-28 | 2020-10-23 | 法明知识产权股份有限公司 | 先兆子痫的治疗和预防 |
WO2019166572A1 (en) | 2018-02-28 | 2019-09-06 | Pharming Intellectual Property B.V. | Pharmaceutical system for transdermal administration of a c1 -esterase inhibitor |
KR20210024048A (ko) | 2018-06-22 | 2021-03-04 | 가부시키가이샤 준텐 바이오 | 복합 상태를 갖는 세포 혼합물을 이용한, 면역 관용을 유도하는 항체 및 유도된 림프구, 또한 유도된 림프구를 이용하는 세포 치료제 및 치료법 |
WO2019245039A1 (ja) | 2018-06-22 | 2019-12-26 | 株式会社Junten Bio | 感染性免疫寛容を惹起するための組成物 |
MX2020014101A (es) | 2018-06-22 | 2021-05-27 | Junten Bio Co Ltd | Anticuerpo que induce tolerancia inmunitaria, linfocito inducido, y agente de terapia celular/metodo terapeutico que usa linfocitos inducidos. |
JPWO2021124793A1 (zh) * | 2019-12-16 | 2021-06-24 | ||
EP3895726A1 (en) | 2020-04-17 | 2021-10-20 | Pharming Intellectual Property BV | Using c1 esterase inhibitor to treat viral infection-related acute respiratory distress |
CA3225079A1 (en) | 2021-07-09 | 2023-01-12 | Bruno Giannetti | Using c1 esterase inhibitor to treat viral infection-related symptoms |
KR20230046146A (ko) | 2021-09-29 | 2023-04-05 | 주식회사 엘지에너지솔루션 | 배터리 제어 시스템 및 방법 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101365478A (zh) * | 2005-12-21 | 2009-02-11 | 法明知识产权股份有限公司 | C1抑制剂在预防缺血-再灌注损伤中的应用 |
WO2013013017A2 (en) * | 2011-07-21 | 2013-01-24 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for modifying the glycosylation of lysosomal storage disorder therapeutics |
CN104080474A (zh) * | 2011-12-22 | 2014-10-01 | 德国杰特贝林生物制品有限公司 | C1-抑制剂在治疗中枢神经系统继发性水肿中的应用 |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5304482A (en) | 1989-03-06 | 1994-04-19 | The Board Of Regents Of The University Of Texas System | Serine protease mutants of the chymotrypsin superfamily resistant to inhibition by their cognate inhibitors |
WO1992022320A1 (en) | 1991-06-14 | 1992-12-23 | Genentech, Inc. | C1 inhibitor variants and treating inflammatory response with c1 inhibitor |
DE69429816T2 (de) | 1993-09-01 | 2002-09-19 | Sanquin Bloedvoorziening | C1-Esterasehemmer zur Verringerung von Myokardschäden bei akutem Herzinfarkt |
EP0868191A1 (en) | 1995-12-18 | 1998-10-07 | Stichting Sanquin Bloedvoorziening | Potentiation of complement and coagulation inhibitory properties of c1-inhibitor. |
AT409336B (de) | 1999-12-22 | 2002-07-25 | Baxter Ag | Verfahren zur herstellung einer c1-esterase-inhibitor (c1-inh)-hältigen zusammensetzung |
PT1252184E (pt) | 2000-01-31 | 2008-04-15 | Pharming Intellectual Pty Bv | Inibidor humano c1 produzido no leite de mamíferos transgénicos |
US7067713B2 (en) | 2000-01-31 | 2006-06-27 | Pharming Intellectual Property B.V. | C1 Inhibitor produced in the milk of transgenic non-human mammals |
AU1344102A (en) | 2000-10-12 | 2002-04-22 | Genentech Inc | Reduced-viscosity concentrated protein formulations |
DE10112617A1 (de) | 2001-03-14 | 2002-10-02 | Aventis Behring Gmbh | Verwendung eines C1-Esterase-Inhibitors zur Verhinderung oder Verzögerung der Abstoßung von Xenotransplantaten in Säugetieren |
WO2004034971A2 (en) | 2002-09-25 | 2004-04-29 | The Center For Blood Research, Inc. | Methods for treating and preventing sepsis using modified c1 inhibitor or fragments thereof |
WO2004110356A2 (en) | 2003-05-15 | 2004-12-23 | Cbr Institute For Biomedical Research, Inc. | Methods for modulating cell-to-cell adhesion using an agonist of c1inh-type protein activity |
USRE43691E1 (en) | 2003-05-16 | 2012-09-25 | Pharming Intellectual Property B.V. | C1 inhibitor with short half-life transient treatment |
US20060233776A1 (en) | 2003-08-19 | 2006-10-19 | Norbert Heimburger | C1-inh as a drug for treating viruses pathogenic to humans |
US8501705B2 (en) | 2003-09-11 | 2013-08-06 | The Board Of Regents Of The University Of Texas System | Methods and materials for treating autoimmune and/or complement mediated diseases and conditions |
EP1598428A1 (en) | 2004-05-18 | 2005-11-23 | Georg Dewald | Methods and kits to detect Hereditary angioedema type III |
EP2529746A1 (en) | 2005-06-06 | 2012-12-05 | Girish J. Kotwal | Methods for treatment or prophylaxis of reperfusion injury |
AU2006304804B2 (en) | 2005-10-21 | 2011-06-02 | Vertex Pharmaceuticals Incorporated | Modified proteases that inhibit complement activation |
KR101508668B1 (ko) | 2005-12-21 | 2015-04-06 | 파밍 인텔렉츄얼 프라퍼티 비.브이. | 허혈-재관류 손상의 예방을 위한 c1 억제제의 용도 |
US7837992B2 (en) | 2006-06-22 | 2010-11-23 | Beth Israel Deaconess Medical Center | C-1 inhibitor prevents non-specific plasminogen activation by a prourokinase mutant without impeding fibrin-specific fibrinolysis |
ES2753183T3 (es) | 2007-02-12 | 2020-04-07 | Csl Behring Gmbh | Aplicación terapéutica de inhibidores de la proteasa de serina de tipo Kazal |
US8883146B2 (en) | 2007-11-30 | 2014-11-11 | Abbvie Inc. | Protein formulations and methods of making same |
CA2707483A1 (en) | 2007-11-30 | 2009-06-11 | Wolfgang Fraunhofer | Protein formulations and methods of making same |
US20100143325A1 (en) | 2008-12-09 | 2010-06-10 | Vascular Laboratory, Inc. | Composition And Methods Involving Thrombolytic Agents |
JP5871798B2 (ja) | 2009-07-02 | 2016-03-01 | エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント | 肝再生を刺激する方法 |
BR112012008970A2 (pt) | 2009-10-16 | 2019-12-10 | Omeros Corp | uso de uma composição, e, composição |
US9815876B2 (en) | 2010-03-05 | 2017-11-14 | Omeros Corporation | Chimeric inhibitor molecules of complement activation |
WO2011116291A1 (en) * | 2010-03-18 | 2011-09-22 | Thrombolytic Science International | Production of human c1 inhibitor in human cells |
EP2758076B1 (en) | 2011-09-24 | 2018-12-12 | CSL Behring GmbH | Combination therapy using immunoglobulin and c1-inhibitor |
JP2015512370A (ja) | 2012-03-16 | 2015-04-27 | ベルローズ ファーマ,インコーポレーテッド | C1−阻害剤のポリマーコンジュゲート |
EP2972375A2 (en) | 2013-03-13 | 2016-01-20 | Creatics LLC | Methods and compositions for detecting pancreatic cancer |
CN111529708A (zh) * | 2013-03-15 | 2020-08-14 | 夏尔维洛药品公司 | 用于预防和治疗与c1酯酶抑制剂缺乏相关的病症的c1-inh组合物和方法 |
-
2014
- 2014-03-17 CN CN202010362851.6A patent/CN111529708A/zh active Pending
- 2014-03-17 MX MX2020004724A patent/MX2020004724A/es unknown
- 2014-03-17 KR KR1020227016244A patent/KR102579789B1/ko active IP Right Grant
- 2014-03-17 SG SG11201507616VA patent/SG11201507616VA/en unknown
- 2014-03-17 CN CN201480014712.7A patent/CN105517559A/zh active Pending
- 2014-03-17 SI SI201431032T patent/SI3290046T1/sl unknown
- 2014-03-17 PL PL14762343T patent/PL2968434T3/pl unknown
- 2014-03-17 NZ NZ710730A patent/NZ710730A/en unknown
- 2014-03-17 KR KR1020157022897A patent/KR20150135242A/ko active Application Filing
- 2014-03-17 PT PT147623433T patent/PT2968434T/pt unknown
- 2014-03-17 CA CA3054718A patent/CA3054718A1/en not_active Abandoned
- 2014-03-17 GB GB1519921.9A patent/GB2530921B/en active Active
- 2014-03-17 DK DK14762343.3T patent/DK2968434T3/en active
- 2014-03-17 SI SI201430368T patent/SI2968434T1/sl unknown
- 2014-03-17 EP EP17177676.8A patent/EP3290046B1/en active Active
- 2014-03-17 ME MEP-2019-45A patent/ME03326B/me unknown
- 2014-03-17 EA EA201591278A patent/EA201591278A1/ru unknown
- 2014-03-17 RS RS20170802A patent/RS56285B1/sr unknown
- 2014-03-17 HU HUE14762343A patent/HUE036224T2/hu unknown
- 2014-03-17 RS RS20190198A patent/RS58351B1/sr unknown
- 2014-03-17 ME MEP-2017-182A patent/ME02865B/me unknown
- 2014-03-17 PL PL17177676T patent/PL3290046T3/pl unknown
- 2014-03-17 WO PCT/US2014/030309 patent/WO2014145519A2/en active Application Filing
- 2014-03-17 HU HUE17177676A patent/HUE041837T2/hu unknown
- 2014-03-17 DK DK17177676.8T patent/DK3290046T3/en active
- 2014-03-17 ES ES14762343.3T patent/ES2639833T3/es active Active
- 2014-03-17 ES ES17177676T patent/ES2713004T3/es active Active
- 2014-03-17 MX MX2015011281A patent/MX2015011281A/es active IP Right Grant
- 2014-03-17 TR TR2019/00319T patent/TR201900319T4/tr unknown
- 2014-03-17 SG SG10201707598QA patent/SG10201707598QA/en unknown
- 2014-03-17 CA CA2904543A patent/CA2904543C/en active Active
- 2014-03-17 AU AU2014232912A patent/AU2014232912A1/en not_active Abandoned
- 2014-03-17 BR BR112015023207A patent/BR112015023207A8/pt not_active Application Discontinuation
- 2014-03-17 LT LTEP17177676.8T patent/LT3290046T/lt unknown
- 2014-03-17 EP EP18206413.9A patent/EP3508213A1/en active Pending
- 2014-03-17 KR KR1020217033628A patent/KR102430453B1/ko active IP Right Grant
- 2014-03-17 EP EP14762343.3A patent/EP2968434B1/en not_active Revoked
- 2014-03-17 PT PT17177676T patent/PT3290046T/pt unknown
- 2014-03-17 NZ NZ751555A patent/NZ751555A/en unknown
- 2014-03-17 LT LTEP14762343.3T patent/LT2968434T/lt unknown
- 2014-03-17 KR KR1020217004777A patent/KR20210021146A/ko not_active IP Right Cessation
- 2014-03-17 DE DE202014011208.8U patent/DE202014011208U1/de not_active Expired - Lifetime
- 2014-03-17 JP JP2016503371A patent/JP6184581B2/ja active Active
-
2015
- 2015-08-28 MX MX2021011946A patent/MX2021011946A/es unknown
- 2015-09-10 IL IL241549A patent/IL241549B/en active IP Right Grant
- 2015-09-15 US US14/855,168 patent/US9616111B2/en active Active
- 2015-10-13 ZA ZA2015/07604A patent/ZA201507604B/en unknown
-
2016
- 2016-07-19 HK HK16108590.9A patent/HK1220403A1/zh unknown
-
2017
- 2017-01-20 US US15/411,744 patent/US20170224788A1/en not_active Abandoned
- 2017-03-16 JP JP2017051361A patent/JP6422520B2/ja active Active
- 2017-08-18 HR HRP20171269TT patent/HRP20171269T1/hr unknown
- 2017-09-12 CY CY20171100961T patent/CY1119419T1/el unknown
- 2017-10-12 ZA ZA2017/06929A patent/ZA201706929B/en unknown
- 2017-12-11 US US15/837,677 patent/US10080788B2/en active Active
- 2017-12-11 US US15/837,693 patent/US10105423B2/en active Active
- 2017-12-11 US US15/837,969 patent/US10201595B2/en active Active
- 2017-12-11 US US15/837,938 patent/US10130690B2/en active Active
-
2018
- 2018-04-06 JP JP2018073690A patent/JP6473535B2/ja active Active
- 2018-04-06 JP JP2018073691A patent/JP6473536B2/ja active Active
- 2018-04-06 JP JP2018073689A patent/JP6473534B2/ja active Active
- 2018-08-02 US US16/053,457 patent/US11534482B2/en active Active
- 2018-08-10 HK HK18110262.0A patent/HK1250912B/zh unknown
- 2018-09-05 US US16/122,015 patent/US20190160158A1/en not_active Abandoned
- 2018-09-17 AU AU2018229558A patent/AU2018229558B2/en active Active
- 2018-10-12 ZA ZA2018/06793A patent/ZA201806793B/en unknown
-
2019
- 2019-01-25 JP JP2019011079A patent/JP6877470B2/ja active Active
- 2019-01-25 JP JP2019011082A patent/JP6877471B2/ja active Active
- 2019-01-25 JP JP2019011084A patent/JP6877472B2/ja active Active
- 2019-02-11 HR HRP20190270TT patent/HRP20190270T1/hr unknown
- 2019-03-15 CY CY20191100308T patent/CY1121653T1/el unknown
- 2019-10-02 US US16/591,184 patent/US11364288B2/en active Active
-
2020
- 2020-05-15 AU AU2020203183A patent/AU2020203183B2/en active Active
- 2020-07-19 IL IL276153A patent/IL276153B/en unknown
-
2021
- 2021-03-02 JP JP2021032716A patent/JP2021088599A/ja active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101365478A (zh) * | 2005-12-21 | 2009-02-11 | 法明知识产权股份有限公司 | C1抑制剂在预防缺血-再灌注损伤中的应用 |
WO2013013017A2 (en) * | 2011-07-21 | 2013-01-24 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for modifying the glycosylation of lysosomal storage disorder therapeutics |
CN104080474A (zh) * | 2011-12-22 | 2014-10-01 | 德国杰特贝林生物制品有限公司 | C1-抑制剂在治疗中枢神经系统继发性水肿中的应用 |
Non-Patent Citations (4)
Title |
---|
BIOONNEWS: "森特贝林(CSL behring)启动C1酯酶抑制剂皮下给药研究", 《WWW.BIOON.COM/INDUSTRY/DRUG/523297.SHTML》 * |
CARTER P.E.ET AL.: "CAA30314", 《GENBANK》 * |
RICHARD G. GOWER ET AL.: "Hereditary Angioedema Caused by C1-Esterase Inhibitor Deficiency: A Literature-Based Analysis and Clinical Commentary on Prophylaxis Treatment Strategies", 《WORLD ALLERGY ORGANIZATION JOURNAL》 * |
无: "Lev公司开发的C1-酯酶抑制剂产品Cinryze在美国获准上市", 《药学进展》 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109562149A (zh) * | 2016-08-05 | 2019-04-02 | 德国杰特贝林生物制品有限公司 | C1酯酶抑制剂的药物制剂 |
CN109641031A (zh) * | 2016-08-23 | 2019-04-16 | 德国杰特贝林生物制品有限公司 | 预防与c1酯酶抑制剂缺乏相关的遗传性血管性水肿急性发作的方法 |
CN110769848A (zh) * | 2017-05-16 | 2020-02-07 | 瑞士奥克特珐玛公司 | C1-酯酶抑制剂制剂 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105517559A (zh) | 用于预防和治疗与c1酯酶抑制剂缺乏相关的病症的c1-inh组合物和方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information |
Address after: Massachusetts, USA Applicant after: Charlotte Pharmaceutical Co.,Ltd. Address before: Massachusetts, USA Applicant before: VIROPHARMA HOLDINGS Ltd. |
|
CB02 | Change of applicant information | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20210903 Address after: Massachusetts, USA Applicant after: WeiLuo pharmaceutical biological preparation Co.,Ltd. Address before: Massachusetts, USA Applicant before: Charlotte Pharmaceutical Co.,Ltd. |
|
TA01 | Transfer of patent application right |